---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-25-105027"
form_type: "8-K"
ticker: "RXST"
cik: "0001111485"
company_name: "RxSight, Inc."
filed_at: "2025-08-07T23:59:59+00:00"
generated_at: "2026-05-17T17:05:30.950457+00:00"
event_type: "earnings"
sentiment: "negative"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# RxSight Q2 revenue $33.6M (-4% YoY); net loss $(11.8)M; reaffirms FY2025 guidance

## Summary
- Total revenue $33.6M, down 4% from $34.9M in Q2 2024; LAL units up 13%, LDD units down 49%.
- Net loss $(11.8)M ($(0.29)/share) vs $(6.1)M loss a year ago; adjusted net loss $(3.2)M.
- Installed LDD base grew 34% to 1,084 units; FDA approved expanded LAL diopter range to -2.0 to +3.0.
- Launched Light Adjustable Lens system in South Korea and Singapore; commercial team realigned.
- Reaffirmed FY2025 revenue guidance $120M-$130M, gross margin 72%-74%, opex $145M-$155M.

## SEC filing metadata
- accession: 0000950170-25-105027
- form_type: 8-K
- ticker: RXST
- cik: 0001111485
- company_name: RxSight, Inc.
- filed_at: 2025-08-07T23:59:59+00:00
- event_type: earnings
- sentiment: negative
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1111485/000095017025105027/0000950170-25-105027-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1111485/000095017025105027/rxst-20250807.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-25-105027
- JSON: https://secwatch.observer/filing/0000950170-25-105027.json
- Plain text: https://secwatch.observer/filing/0000950170-25-105027.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.